Skip to content

Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in OPCAB Patients

Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in Patients Undergoing Coronary Artery Bypass Grafting

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05423951
Enrollment
106
Registered
2022-06-21
Start date
2022-07-26
Completion date
2023-11-08
Last updated
2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic Instability

Keywords

hemodynamics, remimazolam, propofol, coronary artery bypass grafting

Brief summary

Remimazolam is a novel ultra-short-acting benzodiazepine. Several studies demonstrated that its efficacy as a sedative hypnotics for general anesthesia is non-inferior to propofol. However, evidence on the hemodynamic stability of remimazolam for the anesthesia induction in patients undergoing coronary artery bypass grafting is lacking. This prospective randomized trial aims to compare hemodynamic stability during anesthesia induction between remimazolam and propofol in patients undergoing coronary artery bypass grafting.

Interventions

For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.

DRUGPropofol

For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.

DRUGRocuronium

After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed

DRUGSufentanil

During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (aged 19 years or older) who scheduled for elective coronary artery bypass grafting

Exclusion criteria

* Patients who refuse to participate * Concomitant heart valve surgery or thoracic aorta surgery * Emergent surgery * Preoperative sedation * Intubated state * Patients with mechanical circulatory assist device * Preoperative use of inotropes or vasopressors * History of allergy or adverse reaction to study drugs * Rapid sequence intubation * Lactose intolerance * Peanut allergy

Design outcomes

Primary

MeasureTime frameDescription
MAP-time integralDuring 10 minute from the administration of the study drugThe area under the baseline MAP (sec \* mmHg). Baseline MAP was defined as the mean MAP over the 3 min period immediately before induction.

Secondary

MeasureTime frameDescription
Mean blood pressureDuring 10 minute from the administration of the study drugmaximum / minimum value (mmHg)
Heart rateDuring 10 minute from the administration of remimazolam or propofolmaximum / minimum / mean / median / time-weighted average values (bpm)
Regional cerebral oxygen saturationDuring 10 minute from the administration of the study drugcontinuous monitoring of regional cerebral oxygen saturation during surgery (%)
Cardiac outputDuring 10 minute from the administration of the study drugcontinuous monitoring of cardiac output (L/min)
Sufentanil doseDuring 10 minute from the administration of the study drugTotal dose of administered sufentanil (mcg)
CrystalloidDuring 10 minute from the administration of the study drugTotal volume of administered crystalloid (ml)
Time to loss of consciousnessDuring 10 minute from the administration of the study drugThe time from the study drug administration to loss of consciousness
Number of vasopressor administrationDuring 10 minute from the administration of the study drug1. Total number (n) 2. Ephedrine (n) 3. Phenylephrine (n) 4. Vasopressin (n) 5. Norepinephrine (n)
Ephedrine doseDuring 10 minute from the administration of the study drugTotal dose of administered ephedrine (mg)
Phenylephrine doseDuring 10 minute from the administration of the study drugTotal dose of administered phenylephrine (mcg)
Vasopressin doseDuring 10 minute from the administration of the study drugTotal dose of administered vasopressin (unit) 2. Ephedrine: total dose / number of administration 3. Phenylephrine: total dose / number of administration 4. Vasopressin: total dose / number of administration 5. Norepinephrine: total dose / number of administration
Norepinephrine doseDuring 10 minute from the administration of the study drugTotal dose of administered norepinephrine (mcg)
Study drug doseDuring 10 minute from the administration of the study drugTotal dose of administered remimazolam or propofol (mg)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026